Fund moves

Amgen (AMGN): Vaughan David Investments LLC reduced its stake -112K shares

Vaughan David Investments LLC reduced its stake in Amgen, per its Q4 2025 13F.

53K
Shares reported · -112K vs prior quarter
0.38%
Disclosed portfolio weight
$17.3M
Reported value
Holdings as of
Dec 31, 2025
Filed
Feb 12, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 23, 2024CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  2. Nov 19, 2024CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  3. Jan 16, 2026CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  4. Jan 29, 2026CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  5. Jan 30, 2026Company filing · Form 8-K · Agreement endedEnded an important agreement
  6. Feb 3, 2026Company filing · Form 8-K · ResultsReported its results

What came next

  1. Feb 17, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  2. Feb 19, 2026InsiderOfficer sold ~$376K of AMGN shares in the open market
  3. Feb 26, 2026Insider · 1 personInsiders: 2 sales (~$20.8M)
  4. Feb 26, 2026CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  5. Mar 9, 2026Government · Federal Register noticeGranting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
  6. Mar 9, 2026Government · Federal Register noticeAspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
  7. Mar 24, 2026CongressDisclosed purchase of AMGN — reported range $15,001 - $50,000
  8. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  9. Mar 31, 2026Government · Federal Register proposed ruleFiduciary Duties in Selecting Designated Investment Alternatives
  10. Apr 17, 2026CongressDisclosed sale of AMGN — reported range $15,001 - $50,000
  11. Apr 22, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 22, 2026, Amgen Inc. (the “Company”) publicly announced that David M. Reese is retiring from the role of the Company’s Executive Vice President and Chief Technology Officer.”
  12. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  13. Apr 30, 2026Company filing · Form 8-K · ResultsReported its results
  14. Apr 30, 2026Government · Federal Register noticeChemoCentryx, Inc.; Proposal To Withdraw Approval of New Drug Application for TAVNEOS (Avacopan) Capsule, 10 Milligrams; Opportunity for a Hearing
  15. May 4, 2026InsiderOfficer sold ~$400K of AMGN shares in the open market
  16. May 14, 20265% stakeCapital World Investors reported a passive stake (13G) of 5.5%
  17. May 19, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On May 19, 2026, Amgen Inc. (the “Company”) publicly announced that Peter H. Griffith will retire from the role of the Company’s Executive Vice President and Chief Financial Officer, effective August 31, 2026.”
  18. Jun 4, 2026FDARecall: Corlanor (ivabradine) tablets, 7.5mg, 60-count bottles, Rx Only, Amgen Inc., Thousand Oaks, CA 92130 Made In Italy. NDC 55513-810-60
  19. Jun 4, 2026FDARecall: Corlanor (ivabradine) tablets, 5 mg, packaged in a) 14 tablets bottles (NDC 55513-800-99), and b) 60 tablet bottles (NDC 55513-800-60), Rx Only, Amgen Inc., Th…
  20. Jun 4, 2026FDARecall: Sensipar (cinacalcet) Tablets, 60mg, 30-count bottles, Rx Only, Distributed by: Amge, One Amgen Center Drive, Thousand Oaks ,CA 91320-1799, Made in Japan. NDC…
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Amgen

For Amgen, OQRO holds 6 Congress trade reports and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AMGN page.

How this filing works

Explore the data

Common questions

What does this filing report about Amgen (AMGN) stock?

Vaughan David Investments LLC reduced its stake in Amgen, per its Q4 2025 13F. Now 53K shares, $17.3M reported value, 0.38% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Dec 31, 2025. Filed: Feb 12, 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Amgen recently?

For Amgen, OQRO holds 6 Congress trade reports and 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the AMGN page.

Does this mean AMGN stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Amgen

Everything OQRO holds on this company is on its AMGN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data